Skip to content

Sutro Biopharma STRO Total Current Assets

Total Current Assets at other companies

Pfizer logo
PfizerPFE
$42.82B-6.6%
Gilead Sciences logo
Gilead SciencesGILD
$18.64B+10.3%
Regenxbio logo
RegenxbioRGNX
$186.52M-40.5%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
$25.4M-15.8%
Xencor logo
XencorXNCR
$482.86M-7.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$316.11M-12.9%

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AssetsCurrent.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's total current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's total current assets?
Sutro Biopharma (STRO) reported total current assets of $220.97M in Q1 2026.
How has Sutro Biopharma's total current assets changed year-over-year?
Sutro Biopharma's total current assets decreased by 23.1% year-over-year, from $287.41M to $220.97M.
What is the long-term trend for Sutro Biopharma's total current assets?
Over 5 years (2020 to 2025), Sutro Biopharma's total current assets has grown at a -16.8% compound annual growth rate (CAGR), from $378.18M to $150.93M.
What does total current assets mean?
The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.